Oral anticoagulant therapy is used to prevent and treat thromboembolic disease. The new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper reports the consensus of Italian scientific societies dealing with laboratory issues in thrombosis and hemostasis. It is aimed at reviewing: a) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban), b) the patients to be investigated and c) the timing of investigation.
|Translated title of the contribution||Consensus document of Italian Federation of Thrombosis Services (FCSA), Italian Society of Laboratory Medicine (SIMeL), SIBioC e Italian Committee for Standardization of Laboratory Tests (CISMEL) on laboratory monitoring of the therapy with novel oral anticoagulant drugs|
|Number of pages||2|
|Publication status||Published - Aug 2013|
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Medical Laboratory Technology